You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm expects to release an expanded liquid biopsy panel this year to help pharmaceutical partners perform blood-based biomarker discovery work.
The firms will present a clinical comparison study using the workflow to detect FGFR mutations in 50 urothelial cancer patients later this year.
The Spanish firm also expects to release clinical data on its early-stage, next-generation sequencing-based colorectal cancer test in the first half of 2021.
Decipher will remain a wholly owned subsidiary of Veracyte, which plans to integrate Decipher's urologic cancer tests on its nCounter platform.
The firm expects to increase commercial coverage for its pigmented lesion assay for melanoma while widening its pipeline to diagnose other varieties of skin cancer.
The Swedish firm expects to soon receive a CE mark for its Chimerism NGS kit, which identifies hematopoietic stem cell transplant rejection using cellular material.
The firm will consolidate its businesses in newly-built headquarters in Fort Myers, Florida, which it plans to occupy around September.
The firm expects to receive a CE mark later this year for its RT-qPCR breast cancer recurrence assay, which characterizes epithelial CTCs by detecting cytokeratin-19 expression.
The firms will launch a pilot program in three undisclosed US metropolitan regions later this year and collect data from at least 2,000 patients per area.
The firm aims to launch an early-access program by the end of the year, followed by a second white paper before the JP Morgan Healthcare Conference in January.